Your browser doesn't support javascript.
loading
Universities' experience with mumps outbreak response and use of a third dose of MMR vaccine.
Marlow, Mariel; Even, Susan; Hoban, Mary Theresa; Moore, Kelly; Patel, Manisha; Marin, Mona.
Afiliación
  • Marlow M; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Even S; American College Health Association, Hanover, Maryland, USA.
  • Hoban MT; University of Missouri Student Health Center, Columbia, Missouri, USA.
  • Moore K; American College Health Association, Hanover, Maryland, USA.
  • Patel M; Department of Health Policy, Vanderbilt School of Medicine, Nashville, Tennessee, USA.
  • Marin M; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
J Am Coll Health ; 69(1): 53-58, 2021 01.
Article en En | MEDLINE | ID: mdl-31478806
ABSTRACT

OBJECTIVE:

During January 2016-June 2017, 75 mumps outbreaks occurred in US universities, despite high vaccine coverage among students. We evaluated universities' experiences with mumps outbreaks to inform policy deliberations on use of a third dose of MMR vaccine and CDC guidance.

Participants:

American College Health Association members in September 2017.

Methods:

Online survey assessing mumps outbreak characteristics and response measures distributed to 980 members.

Results:

Administrators from 251 (26%) universities from 47 states responded. Seventy-nine (31%) universities had mumps cases on campus during August 2014-August 2017; 17 (22%) recommended a third MMR dose. The main challenges reported in outbreak response were exclusion of persons without presumptive immunity and isolation of students with mumps. Universities' advice on addressing challenges is described.

Conclusion:

We identified common challenges faced by universities during mumps outbreaks, and lessons learned. These findings informed the October 2017 recommendation for use of a third MMR dose.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacuna contra el Sarampión-Parotiditis-Rubéola / Paperas Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Am Coll Health Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacuna contra el Sarampión-Parotiditis-Rubéola / Paperas Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Am Coll Health Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos